| Literature DB >> 26977395 |
Amanda M Ackermann1, Zhiping Wang2, Jonathan Schug3, Ali Naji4, Klaus H Kaestner5.
Abstract
OBJECTIVE: Although glucagon-secreting α-cells and insulin-secreting β-cells have opposing functions in regulating plasma glucose levels, the two cell types share a common developmental origin and exhibit overlapping transcriptomes and epigenomes. Notably, destruction of β-cells can stimulate repopulation via transdifferentiation of α-cells, at least in mice, suggesting plasticity between these cell fates. Furthermore, dysfunction of both α- and β-cells contributes to the pathophysiology of type 1 and type 2 diabetes, and β-cell de-differentiation has been proposed to contribute to type 2 diabetes. Our objective was to delineate the molecular properties that maintain islet cell type specification yet allow for cellular plasticity. We hypothesized that correlating cell type-specific transcriptomes with an atlas of open chromatin will identify novel genes and transcriptional regulatory elements such as enhancers involved in α- and β-cell specification and plasticity.Entities:
Keywords: ARX, aristaless related homeobox; ATAC-seq, Assay for Transposase-Accessible Chromatin with high throughput sequencing; Alpha cell; Beta cell; CHODL, chondrolectin; ChIP-seq, Chromatin Immunoprecipitation followed by high throughput sequencing; DAPI, 4′,6-diamidino-2-phenylindole; DPP4, dipeptidyl-peptidase 4; Diabetes; Epigenetics; FACS, fluorescence-activated cell sorting; FAIRE-seq, Formaldehyde-Assisted Isolation of Regulatory Elements followed by high throughput sequencing; GC, group-specific protein; GCG, glucagon; GHRL, ghrelin; IGF2, insulin like growth factor 2; INS, insulin; IRX2, iroquois homeobox 2; Islet; MAFA, v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog A; NEUROD1, neuronal differentiation 1; Open chromatin; PP, pancreatic polypeptide; SNP, single nucleotide polymorphism; SST, somatostatin
Year: 2016 PMID: 26977395 PMCID: PMC4770267 DOI: 10.1016/j.molmet.2016.01.002
Source DB: PubMed Journal: Mol Metab ISSN: 2212-8778 Impact factor: 7.422
Figure 1ATAC-seq results in sorted human α-, β-, and acinar cells. (A) Experimental design. Islets from deceased organ donors were dispersed and FACS sorted into α-, β-, and acinar cell fractions, and processed for ATAC-seq analysis. N: nucleosome; T: transposase. Red and green bars represent PCR/sequencing barcodes. (B) Fragment lengths within a representative ATAC-seq library. The small fragments represent sequence reads in open chromatin, while the peak at ∼150 bp results from sequence reads that span one nucleosome, and larger peaks represent progressively more compact chromatin. (C) Heatmap of ATAC-seq peak data showing clustering of endocrine-selective peaks (present in α- and β-, but not acinar cells), α-cell-selective peaks, and β-cell-selective peaks. Inter-sample correlation is noted at the bottom. (D) Number of peaks identified by ATAC-seq in each cell type that are specific to that cell type versus also found in either of the other two cell types investigated. (E) Venn diagram of overlap of α-cell-selective and β-cell-selective ATAC-seq peaks, after removal of peaks also found in acinar cells.
Figure 2Integration of ATAC-seq data with other genomics datasets. (A) Bar graph of % of overlapping open chromatin regions identified by FAIRE-seq [32] in whole islets versus by ATAC-seq in α- and β-cells (including peaks also found in acinar cells). Total number of FAIRE-seq peaks is noted at top. (B) Venn diagram of distinct genes with open chromatin regions in α- and β-cells identified by ATAC-seq (including peaks also found in acinar cells) versus in whole islets identified by FAIRE-seq. (C) Sequencing tracks for the ARX locus shows distinct α-cell-specific ATAC-seq peaks at the promoter (black arrow), at known intronic and distal enhancers (red arrows), and at a putative 5′ enhancer (orange arrow), none of which were identified by FAIRE-seq. (D) Histogram of distance from the nearest transcriptional start site (TSS) for all ATAC-seq peaks within 5 kb of the nearest TSS that were identified in α- and β-cells. Not shown are peaks 5–280 kb from the nearest TSS. (E) Proportions of the ATAC-seq peak regions identified in α- and β-cells that represent the various genome annotations, compared to the representation of a given sequence element in the human genome [47].
Figure 3Integration of ATAC-seq data with mRNA-seq, histone marks, FAIRE-seq, and transcription factor binding data for novel α- and β-cell genes. (A) Venn diagrams indicating the proportion of genes that are differentially expressed in α- or β-cells (based on mRNA-seq) that have cell type-selective ATAC-seq peaks (identified only in α- or β-cells, including peaks also identified in acinar cells). (B) Pooled sequencing tracks for the GC locus from α-cell, β-cell, and acinar cell ATAC-seq data (blue); α-cell and β-cell H3K4me3 (green) and H3K4me27 (red) ChIP-seq data; whole islet H2A.Z ChIP-seq data (light blue); and whole islet FAIRE-seq data (pink). Cell type-selective peaks are identified in blue below the row labeled “RefSeq Genes”, followed by islet transcription factor ChIP-seq peaks in purple. Promoter regions are indicated with black arrows, and putative enhancer regions are labeled with orange arrows. (C) Pooled sequencing tracks for the CHODL gene. Annotation as in (B).
α- and β-cell-selective transcripts based on mRNA-seq.
| α-Cell signature genes | β-Cell signature genes | ||||||
|---|---|---|---|---|---|---|---|
| Gene symbol | Any ATAC-seq peak | Peak at promoter | α-cell-specific peak | Gene symbol | Any ATAC-seq peak | Peak at promoter | β-cell-specific peak |
| APOH | ACPP | ||||||
| ARX | X | X | X | ADCYAP1 | X | X | |
| BVES | X | X | X | ANXA8 | |||
| CARTPT | X | X | ASB9 | ||||
| CRH | X | X | ASCL1 | X | |||
| CRYBA2 | BMP5 | ||||||
| DPP4 | X | X | X | CAPN13 | |||
| F10 | X | X | X | CHODL | X | X | X |
| FAM83B | X | X | X | CST2 | |||
| FAP | X | X | CXCL5 | ||||
| GC | X | X | X | DLK1 | |||
| GCG | X | X | X | ESR1 | |||
| GJA3 | X | X | X | GPM6A | X | ||
| IGFBP2 | X | X | GRIN2A | ||||
| IRX2 | X | X | IGF2 | ||||
| LOXL4 | X | X | IGSF11 | ||||
| LPAR1 | X | X | INS | ||||
| MBOAT4 | X | X | X | KRTAP4-7 | |||
| MUC13 | X | X | LAPTM5 | ||||
| MYO10 | X | X | LRFN2 | ||||
| NPNT | LRRTM3 | X | |||||
| POPDC3 | X | X | X | MAFA | |||
| PTPRT | X | X | P2RY1 | X | |||
| SERPINA1 | X | X | X | PCDH7 | X | ||
| SERTM1 | X | X | X | PLCH2 | |||
| SPOCK3 | X | X | PPAPDC1A | ||||
| STK32B | X | X | X | PTGS2 | |||
| SYNDIG | X | X | RGS16 | ||||
| SYTL5 | SIX3 | ||||||
| TM4SF4 | X | X | X | SLC27A6 | X | X | |
| TMEM236 | STEAP3 | X | X | ||||
| TMEM45B | X | X | SULF2 | ||||
| TTR | X | X | X | TFCP2L1 | X | X | |
| TGFBR3 | X | X | |||||
| UNC5D | X | ||||||
Figure 4Immunofluorescent labeling for the novel α-cell-selective protein GC. Whole mount immunofluorescent labeling of human islets (A, C-E) and dispersed human islet cells (B) for GC and the islet hormones as indicated in the figure labels. Yellow arrowheads indicate cells expressing GC and islet hormones. GC: group-specific component; GCG: glucagon; INS: insulin; SST: somatostatin; PP: pancreatic polypeptide; GHRL: ghrelin; DAPI: 4′,6-diamidino-2-phenylindole.
Figure 5Immunofluorescent labeling for the novel β-cell-selective protein CHODL. (A–E) Whole mount immunofluorescent labeling of human islets for CHODL and the islet hormones as indicated in the figure labels. The boxed region in (A) is magnified in (B). CHODL: chondrolectin; GCG: glucagon; INS: insulin; SST: somatostatin; PP: pancreatic polypeptide; GHRL: ghrelin; DAPI: 4′,6-diamidino-2-phenylindole.
Transcription factor binding motifs enriched in α- or β-cell-specific open chromatin regions.
| Factor | Binding Motif | % Regions | P-value |
|---|---|---|---|
| α-Cells | |||
| FRA1/FOSL1 | 21.4% | 10−1145 | |
| FOX | 19.7% | 10−432 | |
| RFX5 | 5% | 10−386 | |
| CTCF | 3.9% | 10−349 | |
| AP4/TFAP4 | 41.2% | 10−235 | |
| RFX4 | 42.5% | 10−181 | |
| ATF2 | 5.4% | 10−139 | |
| ISL1 | 26% | 10−128 | |
| STAT1 | 40.1% | 10−121 | |
| GATA3 | 12.1% | 10−111 | |
| E2F6 | 32.6% | 10−97 | |
| IRF4 | 25.8% | 10−86 | |
| MAFK | 6.9% | 10−84 | |
| MAFB | 76.9% | 10−62 | |
| HAND1 | 13.6% | 10−44 | |
| β-Cells | |||
| FRA1/FOSL1 | 47.2% | 10−264 | |
| LHX2 | 51.4% | 10−92 | |
| AP4/TFAP4 | 23% | 10−32 | |
| CUX1 | 22.4% | 10−30 | |
| FOX | 18.6% | 10−29 | |
| PIT1/POU1F1 | 6.3% | 10−19 | |
| JUN-FOS | 4.2% | 10−18 | |
| SMAD2 | 7% | 10−14 | |
| MEF2C | 3.2% | 10−12 | |
Diabetes risk-associated SNPs near α- or β-cell-specific ATAC-seq peaks.
| SNP | Associated genes | Location in gene | ATAC-seq peak cell type-specificity | Preferential mRNA expression | TF binding sites |
|---|---|---|---|---|---|
| Type 2 diabetes mellitus | |||||
| rs7732130 | Intron | Endocrine cells | Same | NKX6.1, NKX2.2, FOXA2, MAFB | |
| rs7732130 | Intron | Endocrine cells | β-cells | NKX2.2 | |
| rs1169288 | 5’ UTR | Endocrine cells | Same | NKX2.2, FOXA2 | |
| rs1800574 | 5′ UTR | Endocrine cells | Same | NKX2.2, FOXA2 | |
| rs5215 | 5′ UTR | Endocrine cells | β-cells | FOXA2 | |
| rs17066842 | n/a (5′) | Endocrine cells | Same | NKX2.2 | |
| rs13266634 | Intron | Endocrine cells | Same | NKX2.2, FOXA2 | |
| rs11708067 | Intron | α-cells | Same | none | |
| rs10811660 | n/a (5′) | α-cells | Same | MAFB, FOXA2 | |
| rs10757283 | n/a (5′) | α-cells | Same | MAFB, FOXA2 | |
| rs2237895 | Intron | α-cells | Same | NKX2.2, FOXA2 | |
| rs74046911 | Intron | α-cells | Same | NKX2.2, FOXA2 | |
| rs458069 | Intron | α-cells | Same | NKX2.2, FOXA2 | |
| Type 1 diabetes mellitus | |||||
| rs11755527 | Intron | Endocrine cells | Same | None | |
| rs10517086 | none | n/a | Endocrine cells | n/a | None |
TF: transcription factor; UTR: untranslated region; n/a: not applicable.
Located within ATAC-seq peak region. Other SNPs are located within 1,000 bp of ATAC-seq peak region and TF binding sites.